A Randomized, Double‐Blind, Placebo‐Controlled Multicenter Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Pegloticase: 12‐Month Findings
Objective To assess 12‐month safety and efficacy of pegloticase + methotrexate (MTX) versus pegloticase + placebo (PBO) cotherapy in a PBO‐controlled, double‐blind trial (A randomized, double‐blind, placebo‐controlled, multicenter, efficacy and safety study of methotrexate to increase response rates...
Main Authors: | John K. Botson, Kenneth Saag, Jeff Peterson, Katie Obermeyer, Yan Xin, Brian LaMoreaux, Lissa Padnick‐Silver, Supra Verma, Suneet Grewal, Amar Majjhoo, John R. P. Tesser, Michael E. Weinblatt |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-08-01
|
Series: | ACR Open Rheumatology |
Online Access: | https://doi.org/10.1002/acr2.11578 |
Similar Items
-
Improved joint and patient-reported health assessments with pegloticase plus methotrexate co-therapy in patients with uncontrolled gout: 12-month exploratory outcomes of the MIRROR open-label trial
by: John K. Botson, et al.
Published: (2022-12-01) -
A multicentre, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase (MIRROR): 12-month efficacy, safety, immunogenicity, and pharmacokinetic findings during long-term extension of an open-label study
by: John K. Botson, et al.
Published: (2022-08-01) -
Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation
by: Emily E. Holladay, et al.
Published: (2024-04-01) -
Comparison Between Early-Onset and Common Gout: A Systematic Literature Review
by: Anthony J. Amatucci, et al.
Published: (2023-06-01) -
New advances in the treatment of gout: review of pegloticase
by: Mattheus K Reinders, et al.
Published: (2010-10-01)